Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice.
Choi A, Bouzya B, Cortés Franco KD, Stadlbauer D, Rajabhathor A, Rouxel RN, Mainil R, Van der Wielen M, Palese P, García-Sastre A, Innis BL, Krammer F, Schotsaert M, Mallett CP, Nachbagauer R. Choi A, et al. Among authors: mallett cp. Immunohorizons. 2019 Apr 1;3(4):133-148. doi: 10.4049/immunohorizons.1900022. Immunohorizons. 2019. PMID: 31032479 Free PMC article.
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts.
Nachbagauer R, Salaun B, Stadlbauer D, Behzadi MA, Friel D, Rajabhathor A, Choi A, Albrecht RA, Debois M, García-Sastre A, Rouxel RN, Sun W, Palese P, Mallett CP, Innis BL, Krammer F, Claeys C. Nachbagauer R, et al. Among authors: mallett cp. NPJ Vaccines. 2019 Dec 6;4:51. doi: 10.1038/s41541-019-0147-z. eCollection 2019. NPJ Vaccines. 2019. PMID: 31839997 Free PMC article.
Chimeric hemagglutinin supra-seasonal universal influenza vaccine candidates administered sequentially by the intramuscular route are locally and systemically well-tolerated in rabbits.
Destexhe É, Grosdidier É, Bouhraoua A, Thirion-Delalande C, Bouzya B, Rouxel RN, Mallett CP, Baumeister J. Destexhe É, et al. Among authors: mallett cp. Regul Toxicol Pharmacol. 2020 Jun;113:104625. doi: 10.1016/j.yrtph.2020.104625. Epub 2020 Feb 28. Regul Toxicol Pharmacol. 2020. PMID: 32119974
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.
Folschweiller N, Vanden Abeele C, Chu L, Van Damme P, García-Sastre A, Krammer F, Nachbagauer R, Palese P, Solórzano A, Bi D, David MP, Friel D, Innis BL, Koch J, Mallett CP, Rouxel RN, Salaun B, Vantomme V, Verheust C, Struyf F. Folschweiller N, et al. Among authors: mallett cp. Lancet Infect Dis. 2022 Jul;22(7):1062-1075. doi: 10.1016/S1473-3099(22)00024-X. Epub 2022 Apr 21. Lancet Infect Dis. 2022. PMID: 35461522 Clinical Trial.
Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity.
Levine MZ, Holiday C, Bai Y, Zhong W, Liu F, Jefferson S, Gross FL, Tzeng WP, Fries L, Smith G, Boutet P, Friel D, Innis BL, Mallett CP, Davis CT, Wentworth DE, York IA, Stevens J, Katz JM, Tumpey T. Levine MZ, et al. Among authors: mallett cp. Vaccines (Basel). 2022 Nov 1;10(11):1856. doi: 10.3390/vaccines10111856. Vaccines (Basel). 2022. PMID: 36366364 Free PMC article.
54 results